Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

被引：58

作者：

Griesinger, Georg ^{[1
]}

Tournaye, Herman ^{[2
]}

Macklon, Nick ^{[3
,4
]}

Petraglia, Felice ^{[5
]}

Arck, Petra ^{[6
]}

Blockeel, Christophe ^{[2
]}

van Amsterdam, Peter ^{[7
]}

Pexman-Fieth, Claire ^{[8
]}

Fauser, Bart C. J. M. ^{[9
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Gynecol Endocrinol & Reprod Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany

[2] Univ Ziekenhuis Brussel, Ctr Reprod Med, Laarbeeklaan 101, B-1090 Brussels, Belgium

[3] Univ Copenhagen, Zealand Univ Hosp, Dept Obstet & Gynaecol, Alleen 15, DK-4180 Roskilde, Denmark

[4] London Womens Clin, 113-115 Harley St, London W1G 6AP, England

[5] Univ Florence, Dept Biomed Expt & Clin Sci, Obstet & Gynecol, Piazzale Brambilla 3, I-50134 Florence, Italy

[6] Univ Med Ctr Hamburg Eppendorf, Dept Obstet & Fetal Med, Martinistr 52, D-20246 Hamburg, Germany

[7] Abbott Healthcare Prod BV, CJ van Houtenlaan 36, NL-1381 CP Weesp, Netherlands

[8] Abbott GmbH & Co KG, Max Planck Ring 2, D-65205 Wiesbaden, Germany

[9] Univ Med Ctr Utrecht, Dept Reprod Med & Gynecol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

来源：

REPRODUCTIVE BIOMEDICINE ONLINE | 2019年 / 38卷 / 02期

关键词：

Duphaston; Dydrogesterone; In-vitro fertilization; Luteal phase support; Pharmacological profile; Progesterone; IN-VITRO FERTILIZATION; MICRONIZED VAGINAL PROGESTERONE; FOLLICLE-STIMULATING-HORMONE; CONGENITAL HEART-DISEASE; NITRIC-OXIDE SYNTHESIS; ORAL DYDROGESTERONE; LUTEINIZING-HORMONE; OVARIAN STIMULATION; EARLY-PREGNANCY; INTRAMUSCULAR PROGESTERONE;

D O I：

10.1016/j.rbmo.2018.11.017

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.

引用

页码：249 / 259

页数：11

共 112 条

[11] Preimplantation hormonal differences between the conception and non-conception menstrual cycles of 32 normal women [J].

Baird, DD ;

Wilcox, AJ ;

Weinberg, CR ;

Kamel, F ;

McConnaughey, DR ;

Musey, PI ;

Collins, DC .

HUMAN REPRODUCTION, 1997, 12 (12) :2607-2613

[12] Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials [J].

Barbosa, M. W. P. ;

Silva, L. R. ;

Navarro, P. A. ;

Ferriani, R. A. ;

Nastri, C. O. ;

Martins, W. P. .

ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2016, 48 (02) :161-U53

[13]

Bayer Schering Pharma AG, 2007, PROL DEP 250 MG PRES

[14] Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment [J].

Beckers, NGM ;

Macklon, NS ;

Eijkemans, MJ ;

Ludwig, M ;

Felberbaum, RE ;

Diedrich, K ;

Bustion, S ;

Loumaye, E ;

Fauser, BCJM .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4186-4192

[15]

BELL ET, 1965, LANCET, V1, P403

[16] Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support [J].

Beltsos, Angeline N. ;

Sanchez, Mark D. ;

Doody, Kevin J. ;

Bush, Mark R. ;

Domar, Alice D. ;

Collins, Michael G. .

REPRODUCTIVE HEALTH, 2014, 11

[17]

Benagiano G, 2009, PATIENT PREFER ADHER, V3, P131

[18]

Besins Healthcare UK Ltd, 2017, UTR VAG 200 MG CAPS

[19]

BINGHAM JS, 1984, BRIT J VENER DIS, V60, P175

[20] EFFECT OF DYDROGESTERONE ON HUMAN ENDOMETRIUM AND OVARIAN ACTIVITY [J].

BISHOP, PMF ;

DICZFALUSY, E ;

TILLINGER, KG ;

BORELL, U .

ACTA ENDOCRINOLOGICA, 1962, 40 (02) :203-&

← 1 2 3 4 5 6 7 8 9 10 →